Navigation
-
UPDATE -- Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
-
Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research
-
Advaxis to Present at Barclays Global Healthcare Conference
-
Advaxis Elects Gregory Mayes, Executive Vice President and Chief Operating Officer, to Board of Directors
-
Advaxis Truly Personalized Cancer Immunotherapy Moves Forward With Signing of an Exclusive Supply Agreement With Synthetic Genomics for Synthetic DNA
-
Dosing Begins in High Dose Expansion Cohort in Phase 2 Study of Axalimogene Filolisbac in Patients With Recurrent Cervical Cancer
-
Advaxis to Present at 27th Annual ROTH Conference
-
Advaxis Study in Head and Neck Cancer Selected for Late-Breaking Poster at the American Association for Cancer Research Annual Meeting
-
Advaxis to Present at Cowen’s 36th Annual Health Care Conference
-
Advaxis to Present at 2016 RBC Capital Markets’ Healthcare Conference
